Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: Effect of cotreatment for tuberculosis

Journal of Infectious Diseases

Volumn 201, Issue 8, 2010, Pages 1121-1131

  Reitz, Cordula ^a   Coovadia, Ashraf ^d   Ko, Stephen ^c   Meyers, Tammy ^e   Strehlau, Renate ^d   Sherman, Gayle ^f   Kuhn, Louise ^a   Abrams, Elaine J ^b  

^a Department of Obstetrics Gynecology   (United States)

^b Mailman School of Public Health ^*  (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ETHIONAMIDE; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; STAVUDINE; VIRUS RNA;

ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; SOUTH AFRICA; SURVIVAL; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ETHIONAMIDE; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT; ISONIAZID; KAPLAN-MEIERS ESTIMATE; MALE; PYRIMIDINONES; RIFAMPIN; RITONAVIR; RNA, VIRAL; SOUTH AFRICA; TUBERCULOSIS, PULMONARY; VIRAL LOAD;

EID: 77950190296     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651454     Document Type: Article

References (37)

1. Joint United Nations Programme on HIV/AIDS and World Health Organization (WHO). AIDS epidemic update. Vol.UNAIDS/07.27E/ JC1322E. Geneva, Switzerland: WHO, 2007.
2. Obimbo EM, Wamalwa D, Richardson B, et al. Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mor-tality. J Acquir Immune Defic Syndr 2009;51: 209-215.
3. + lymphocyte count in HIV-infected infants and children. JAMA 1998;279: 756-761.
4. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis E Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004;364: 1236-1243.
5. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008;8: 477-489.
6. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359: 2233-2244.
7. World Health Organization (WHO). Revised treatment recommen-dations for infants. Geneva, Switzerland: WHO, 2008:1-10.
8. Jaspan HB, Berrisford AE, Boulle AM. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhib-itor regimens in a South African pediatric antiretroviral program. Pe-diatr Infect Dis J 2008;27: 993-998.
9. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodefi-ciency virus-infected children. Pediatr Infect Dis J 2003;22: 216-224.
10. Smith K, Kuhn L, Coovadia A, et al. Immune reconstitution inflam-matory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS 2009;23: 1097-1107.
11. South African Government Department of Health. Guidelines for the management of HIV-infected children, section 10: antiretroviral. De-partment of Health Web site, http://www.doh.gov.za/docs/factsheets/ guidelines/hiv/part5. pdf. Published 2005. Accessed 14 February 2010.
12. Mcllleron H, Ren Y, Nuttall J, et al. Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifam-picin-based anti-TB treatment. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (CROI). Al-exandria, VA: CROI, 2009. Abstract 98.
13. Hausier H. Tuberculosis and HIV/AIDS: clinical guidelines. Cape Town, South Africa: National Department of Health, 1999.
14. Chadwick EG, Rodman JH, Britto P, et al. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-in-fected infants younger than 24 months of age. Pediatr Infect Dis J 2005; 24: 793-800.
15. Walker AS, Doerholt K, Sharland M, Gibb DM. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Col-laborative HIV Paediatric Study. AIDS 2004;18: 1915-1924.
16. KIDS-ART-LINC Collaboration. Low risk of death, but substantial pro-gram attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2008;49: 523-531.
17. Bekker V, Scherpbier HJ, Steingrover R, et al. Viral dynamics after starting first-line HAART in HIV-1-infected children. AIDS 2006; 20: 517-523.
18. Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ri-tonavir in stable antiretroviral therapy-experienced HIV-infected chil-dren: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 2000;283: 492-498.
19. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999;341: 1874-1881.
20. Watson DC, Farley JJ. Efficacy of and adherence to highly active an-tiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999;18: 682-689.
21. Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007;334: 136.
22. World Health Organization (WHO). A research agenda for childhood tu-berculosis: improving the management of childhood tuberculosis with-in national tuberculosis programmes: research priorities based on a lit-erature review. 2007 ed. Vol.WHO/HTM/TB/2007.381. Geneva, Swit-zerland: WHO, 2007: 1-124.
23. Centers for Disease Control and Prevention (CDC). TB and HIV/AIDS facts. January 2008 ed. Atlanta, GA: CDC, 2008.
24. Rabie H, Violari A, Madhi S, et al. Complications of BCG vaccination in HIV-infected and -uninfected children: CHER Study. In: Program and abstracts of the 15th Conference on Retroviruses and Opportu-nistic Infections (CROI). Alexandria, VA: CROI, 2008. Abstract 600.
25. Burger D, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ri-tonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3336-3342.
26. La Porte C, Colbers E, Bertz RJ. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. An-timicrob Agents Chemother 2004;48: 1553-1560.
27. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530-539.
28. Breen RA, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006; 193: 1437-1440.
29. Edwards S, Dean G, Matthews G, et al. Does tuberculosis (TB) treatment alter immunological and virological response to HAART? In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (CROI). Alexandria, VA: CROI, 2009. Ab-stract 256.
30. Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003;17: 2615-2622.
31. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005;19: 2109-2116.
32. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006;20: 1605-1612.
33. Schaaf HS, Willemse M, Cilliers K, et al. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med 2009;7: 19.
34. McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concen-trations in a cohort of South African children with tuberculosis: im-plications for international pediatric dosing guidelines. Clin Infect Dis 2009;48: 1547-1553.
35. Davies MA, Boulle A, Fakir T, Nuttall J, Eley B. Adherence to anti-retroviral therapy in young children in Cape Town, South Africa, mea-sured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr 2008;8: 34.
36. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189: 51-60.
37. Faye A, Bertone C, Teglas JP, et al. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J 2002;21: 518-525.